A5020718986- Allergic Rhinitis and Sensitization
- Food Allergy and Anaphylaxis Research
- Transgenic Plants and Applications
- Asthma and respiratory diseases
- Monoclonal and Polyclonal Antibodies Research
- Vaccine Coverage and Hesitancy
- RNA Interference and Gene Delivery
- Inhalation and Respiratory Drug Delivery
- Immunotherapy and Immune Responses
- Viral Infectious Diseases and Gene Expression in Insects
- Toxin Mechanisms and Immunotoxins
- CRISPR and Genetic Engineering
- Dermatology and Skin Diseases
- Extracellular vesicles in disease
- Pharmaceutical studies and practices
Allergen immunotherapy (AIT) is the only disease-modifying treatment with evidence for sustained efficacy. However, it poorly developed compared to symptomatic drugs. The main reasons come from duration implying monthly injections during 3 5 years or daily sublingual use, and risk of allergic side-effects. To become a more attractive alternative lifelong drug improvements AIT are needed. Among most promising new strategies use bioparticles presentation target antigen immune system as they...
To the Editor, Allergen immunotherapy (AIT) is only disease-modifying treatment for allergic diseases with proven sustained efficacy, but long duration, chronic exposure to aluminium salts and side-effects are major drawbacks. AIT aims redirect underlying T helper type 2 (Th2)-skewed immune response towards an allergen-specific mixed 1 (Th1)/regulatory cell (Treg) response.1 Recently, plant-made enveloped eBioparticles (eBPs) were introduced as allergen expression platform display...
As the only market-authorized allergen immunotherapy (AIT) for peanut allergy is accompanied by a high risk of side effects and mainly induces robust desensitization without sustained efficacy, novel treatment options are required. Peanut-specific plant-derived eBioparticles (eBPs) surface expressing Ara h 2 at density have been shown to be very hypoallergenic. Here, we assessed dendritic cell (DC)-activating T polarization capacity these peanut-specific eBPs.Route kinetics eBP uptake were...
Canine atopic dermatitis (CAD) is an allergic, inflammatory, and pruritic skin disease associated with the production of IgE antibodies against environmental allergens mainly house dust mite allergens. This complex dermatological pathology involves Interleukin 31 (IL-31) as a central itch mediator. One most effective CAD treatments caninized monoclonal antibody (mAb) called Lokivetmab. It produced in CHO cells targets specifically canine IL-31 (cIL-31) blocks its cellular messaging....
Allergen-carrying virus-like particles are effective and safe means of allergen immunotherapy (AIT) in rodent models.
Summary Prevention of severe COVID‐19 disease by SARS‐CoV‐2 in high‐risk patients, such as immuno‐compromised individuals, can be achieved administration antibody prophylaxis, but producing antibodies costly. Plant expression platforms allow substantial lower production costs compared to traditional bio‐manufacturing depending on mammalian cells bioreactors. In this study, we describe the expression, and purification originally human COVA2‐15 plants. Our plant‐produced mAbs demonstrated...
Current allergen products carry significant limits in terms of their quality and consistency this likely accounts for shortcomings the clinical diagnosis allergy its treatment through desensitization. Increasingly, stakeholders (clinicians, pharmaceutical industry regulatory agencies) are seeking better, more effective aligned with principles Precision Medicine.